terazosin has been researched along with Obesity in 2 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alonso-Galicia, M | 1 |
Brands, MW | 1 |
Zappe, DH | 1 |
Hall, JE | 1 |
Antic, V | 1 |
Kiener-Belforti, F | 1 |
Tempini, A | 1 |
Van Vliet, BN | 1 |
Montani, JP | 1 |
2 other studies available for terazosin and Obesity
Article | Year |
---|---|
Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; | 1996 |
Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Pressure D | 2000 |